NASDAQ · INDP
Healthcare · Biotechnology
$3.64
Up+$0.50 (+15.92%)
Updated Sep 16, 2026, 11:12 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INDP closed at $3.64 after 20 trading sessions, up 288.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.40 | $3.6947 | $3.05 | $3.64 | 1.96M |
| Sep 14, 2026 | $2.80 | $3.18 | $2.69 | $3.14 | 1.39M |
| Sep 11, 2026 | $2.70 | $2.94 | $2.46 | $2.77 | 1.8M |
| Sep 10, 2026 | $2.00 | $2.63 | $1.97 | $2.56 | 3.18M |
| Sep 9, 2026 | $1.92 | $2.39 | $1.89 | $2.08 | 5.68M |
| Sep 8, 2026 | $1.285 | $1.94 | $1.27 | $1.85 | 8.46M |
| Sep 4, 2026 | $1.20 | $1.235 | $1.17 | $1.22 | 133.11K |
| Sep 3, 2026 | $1.16 | $1.19 | $1.14 | $1.16 | 249.92K |
| Sep 2, 2026 | $1.17 | $1.20 | $1.1312 | $1.17 | 331.83K |
| Sep 1, 2026 | $1.10 | $1.162 | $1.10 | $1.13 | 75.3K |
| Aug 31, 2026 | $1.14 | $1.17 | $1.09 | $1.145 | 140.26K |
| Aug 28, 2026 | $1.16 | $1.1845 | $1.10 | $1.14 | 104.08K |
| Aug 27, 2026 | $1.13 | $1.24 | $1.09 | $1.16 | 404.59K |
| Aug 26, 2026 | $1.09 | $1.16 | $1.06 | $1.14 | 206.02K |
| Aug 25, 2026 | $1.15 | $1.18 | $1.09 | $1.095 | 497.16K |
| Aug 24, 2026 | $1.24 | $1.29 | $1.13 | $1.16 | 293.73K |
| Aug 21, 2026 | $1.39 | $1.58 | $1.18 | $1.29 | 1.14M |
| Aug 20, 2026 | $0.9419 | $1.42 | $0.94 | $1.38 | 11.75M |
| Aug 19, 2026 | $0.9361 | $1.11 | $0.925 | $0.94 | 813.18K |
| Aug 18, 2026 | $1.00 | $1.02 | $0.92 | $0.9361 | 341.45K |
The latest Smart Investors Daily articles mentioning INDP.
INDP research
Company profile and research snapshot.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 13, 2024 | Maxim Group | Buy | — |
| Oct 16, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 17, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 15, 2024 | HC Wainwright & Co. | Buy | — |
| Sep 20, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 10, 2026
The Company currently intends to use the net proceeds from the Private Placement for working capital, research and development and other general corporate purposes, which may include early-stage research and preclinical
Benzinga · Aug 17, 2026
https://www.sec.gov/Archives/edgar/data/1857044/000149315226038780/forms-3.htm
Benzinga · Aug 13, 2026
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(1.57) by 98.73 percent. This is a 99.78 percent increase over losses of $(9.09) per share
Benzinga · Jun 26, 2026
https://www.sec.gov/Archives/edgar/data/1857044/000149315226030346/forms-3.htm
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INDP.
